| Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab C Hua, L Boussemart, C Mateus, E Routier, C Boutros, H Cazenave, ... JAMA dermatology 152 (1), 45-51, 2016 | 661 | 2016 |
| BMP-4 is required for hepatic specification of mouse embryonic stem cell–derived definitive endoderm V Gouon-Evans, L Boussemart, P Gadue, D Nierhoff, CI Koehler, A Kubo, ... Nature biotechnology 24 (11), 1402-1411, 2006 | 523 | 2006 |
| eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies L Boussemart, H Malka-Mahieu, I Girault, D Allard, O Hemmingsson, ... Nature 513 (7516), 105-109, 2014 | 373 | 2014 |
| L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus EG Cormier, RJ Durso, F Tsamis, L Boussemart, C Manix, WC Olson, ... Proceedings of the National Academy of Sciences 101 (39), 14067-14072, 2004 | 327 | 2004 |
| Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients L Boussemart, E Routier, C Mateus, K Opletalova, G Sebille, ... Annals of oncology 24 (6), 1691-1697, 2013 | 226 | 2013 |
| Skin tumors induced by sorafenib; paradoxic RAS–RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1 JP Arnault, C Mateus, B Escudier, G Tomasic, J Wechsler, E Hollville, ... Clinical cancer research 18 (1), 263-272, 2012 | 139 | 2012 |
| Vemurafenib and radiosensitization L Boussemart, C Boivin, J Claveau, YG Tao, G Tomasic, E Routier, ... JAMA dermatology 149 (7), 855-857, 2013 | 101 | 2013 |
| Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma S Corre, N Tardif, N Mouchet, HM Leclair, L Boussemart, A Gautron, ... Nature communications 9 (1), 4775, 2018 | 91 | 2018 |
| Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports L Boussemart, S Jacobelli, F Batteux, C Goulvestre, P Grange, A Carlotti, ... Dermatology 221 (3), 201-205, 2010 | 76 | 2010 |
| Secondary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF–CRAF heterodimerization L Boussemart, I Girault, H Malka-Mahieu, C Mateus, E Routier, ... Cancer research 76 (6), 1476-1484, 2016 | 46 | 2016 |
| Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti–PD-1 therapy L Dousset, F Poizeau, C Robert, S Mansard, L Mortier, C Caumont, ... JCO precision oncology 5, 1821-1829, 2021 | 44 | 2021 |
| Polymorphism screening of PIK4CA: Possible candidate gene for chromosome 22q11‐linked psychiatric disorders T Saito, P Stopkova, L Diaz, DF Papolos, L Boussemart, HM Lachman American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 116 …, 2003 | 37 | 2003 |
| Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors M Holderfield, E Lorenzana, B Weisburd, L Lomovasky, L Boussemart, ... Cancer research 74 (8), 2238-2245, 2014 | 35 | 2014 |
| Cancer predisposition and germline CTNNA1 variants S Lobo, PR Benusiglio, F Coulet, L Boussemart, L Golmard, I Spier, ... European journal of medical genetics 64 (10), 104316, 2021 | 30 | 2021 |
| Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies A Frelau, X Palard-Novello, E Jali, L Boussemart, A Dupuy, P James, ... Cancer Immunology, Immunotherapy 70, 679-687, 2021 | 15 | 2021 |
| Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies WG Philipp-Dormston, M Battistella, L Boussemart, A Di Stefani, ... Journal of Dermatological Treatment 31 (6), 576-582, 2020 | 14 | 2020 |
| Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? B Baroudjian, L Boussemart, E Routier, B Dreno, Y Tao, E Deutsch, ... European Journal of Dermatology 24 (2), 265-267, 2014 | 13 | 2014 |
| Implementation of a molecular tumor board at a regional level to improve access to targeted therapy H Bourien, A Lespagnol, B Campillo-Gimenez, I Felten-Vinot, JP Metges, ... International Journal of Clinical Oncology 25, 1234-1241, 2020 | 12 | 2020 |
| Melanoma tumour vasculature heterogeneity: From mice models to human V Pautu, A Mellinger, P Resnier, E Lepeltier, L Martin, L Boussemart, ... Journal of cancer research and clinical oncology 145, 589-597, 2019 | 12 | 2019 |
| First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants M Coudert, Y Drouet, H Delhomelle, M Svrcek, PR Benusiglio, F Coulet, ... Journal of medical genetics 59 (12), 1189-1195, 2022 | 11 | 2022 |
